07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Asceneuron's clinical path

Investors pulled the trigger on a CHF30 million ($30.7 million) A round for preclinical neurology play Asceneuron S.A. last week thanks to a combination of in vivo proof-of-concept data and advances in neurological imaging technologies...
01:05 , Sep 30, 2015 |  BC Extra  |  Financial News

Asceneuron raises CHF30 million series A round

Neurology company Asceneuron S.A. (Lausanne, Switzerland) raised CHF30 million ($30.7 million) in a series A round led by new investor Sofinnova Partners. Also participating were new investors SR One; Kurma Partners; and Johnson & Johnson...
08:00 , Mar 2, 2015 |  BioCentury  |  Emerging Company Profile

The road to Tau

Asceneuron S.A. is working to treat neurodegeneration by preventing formation of neurofibrillary tangles in the hopes this mechanism will fare better in treating Alzheimer's disease than amyloid-targeted products. Neurofibrillary tangles arise when microtubule-associated protein tau...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

Summit preclinical data

In a mouse model of tauopathy, Summit's Seglin O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors given daily for 10 weeks non-significantly reduced mean hind limb clasping scores and improved survival rates vs. vehicle-treated controls (p>0.05 for both). Additionally,...
07:00 , Sep 17, 2012 |  BioCentury  |  Tools & Techniques

BMS's high carb diet

Bristol-Myers Squibb Co. is placing a small wager that Seglin carbohydrate technology from Summit Corp. plc can deliver the stability and specificity that earlier generations of carbohydrate-based drugs could not. For Summit, a recent shift...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Summit musculoskeletal, infectious news

Summit said it will focus on the clinical development of programs for Duchenne muscular dystrophy (DMD) and Clostridium difficile infections. The company said the change in strategy will "curtail internal discovery-stage research," which is conducted...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

Summit preclinical data

In a human cell model of tauopathy, Summit's Seglin O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors significantly reduced tau phosphorylation vs. both vehicle-treated and positive controls. Data were presented at the International Conference on Alzheimer's Disease in Paris....
07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Aquapharm, University of Dundee deal

The biotech and the university will develop therapeutics based on natural marine products targeting O-linked N-acetylglucosaminidase (O-GIcNAcase) to treat Alzheimer's disease (AD). Aquapharm will fund the research and provide access to extracts from its culture...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

Alectos Therapeutics, Merck deal

Alectos partnered with Merck to discover and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) for Alzheimer's disease (AD) and other potential disorders. The companies will jointly collaborate on discovery and preclinical development, after which Merck...
07:00 , Aug 16, 2010 |  BioCentury  |  Product Development

New tack on tau

Merck & Co. Inc. has signed on to a novel way of tackling tau, a key component of the neurofibrillary tangles in Alzheimer's disease. Last week the pharma unveiled a co-development deal with Alectos Therapeutics...